Prelude Therapeutics Inc 8-K

What Happened
Prelude Therapeutics Inc. announced on April 20, 2026 that it entered into an underwriting agreement to sell 18,018,014 shares of common stock at $4.44 per share and pre-funded warrants to purchase up to 2,252,252 shares at $4.4399 per warrant (exercise price $0.0001). The offering was led by new investor RA Capital Management with participation from Soleus Capital and others, and was underwritten by representatives Goldman Sachs & Co. LLC and Evercore Group L.L.C. Prelude estimates net proceeds of approximately $85.5 million (assuming no exercise of the pre-funded warrants) and expects the offering to close on April 21, 2026, subject to customary closing conditions.

Key Details

• Offering priced April 20, 2026; expected close April 21, 2026.
• 18,018,014 common shares at $4.44 per share; 2,252,252 pre-funded warrants at $4.4399 each (exercise $0.0001).
• Estimated net proceeds ≈ $85.5 million after underwriting discounts, commissions and offering expenses (assuming no warrant exercises).
• Prelude says combined cash, equivalents and investments plus these proceeds are expected to fund operations into the second quarter of 2028.

Why It Matters
This transaction provides Prelude with additional capital to fund research, preclinical and clinical development and general corporate needs, extending its reported cash runway into mid-2028. The issuance will increase the company’s potential share count if the pre-funded warrants are exercised; investors should watch the final close, any future warrant exercises and subsequent dilution when assessing share value and runway assumptions.